223MO Five-year outcomes of participants with pathological complete response (pCR) enrolled in the KEYNOTE-671 trial of perioperative pembrolizumab (pembro) in early-stage NSCLC

ESMO Open 2026 Open access

Read full text
Authors: M. Majem, M. Garassino, C. Dooms, E. Eigendorff, G.L. Martinengo, O. Bylicki, D. Rodriguez Abreu, S. Novello, E. Nadal, A. Lowczak, D. De Almeida Matias, A. Luft
+6 more B. Mennecier, A. Rittmeyer, E. Jensen, S. Keller, Ayman Samkari, J. Spicer
DOI: 10.1016/j.esmoop.2026.106531
Cited by: 3

Abstract

In the phase 3 KEYNOTE-671 study of early-stage NSCLC, perioperative pembro plus neoadjuvant chemotherapy (chemo) significantly improved event-free survival (EFS), overall survival (OS), major pathological response, and pCR vs neoadjuvant chemo. EFS was prolonged in exploratory analyses of participants (pts) who achieved pCR (HR, 0.33; 95% CI, 0.09–1.22). We report efficacy results in pts with pCR from KEYNOTE-671 after 5 years of follow-up.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Diagnosis and Treatment Colorectal and Anal Carcinomas

Publication details

Journal / source
ESMO Open
Publisher
Elsevier BV
Volume
11
Pages
106531–106531
Publication date
17 March 2026
Language
EN